Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcitonin porcine is a polypeptide hormone derived from the parafollicular cells of the thyroid gland in pigs. It acts primarily by binding to specific receptors on osteoclasts, inhibiting their activity and thereby reducing bone resorption. This leads to decreased serum and urinary calcium concentrations and helps maintain or increase bone mass without adversely affecting cortical bone. Calcitonin porcine was historically used for conditions such as Paget's disease of bone and osteoporosis; it was the first commercially available preparation of calcitonin in Britain under the brand name Calcitare. In clinical studies, it improved symptoms associated with Paget's disease but showed limited efficacy in osteoporosis[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcitonin porcine.